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BACKGROUND
Management of degenerative spondylolisthesis with spinal stenosis is controversial. 
Surgery is widely used, but its effectiveness in comparison with that of nonsurgical 
treatment has not been demonstrated in controlled trials.
METHODS
Surgical candidates from 13 centers in 11 U.S. states who had at least 12 weeks of 
symptoms and image-confirmed degenerative spondylolisthesis were offered en-
rollment in a randomized cohort or an observational cohort. Treatment was stan-
dard decompressive laminectomy (with or without fusion) or usual nonsurgical care. 
The primary outcome measures were the Medical Outcomes Study 36-Item Short-
Form General Health Survey (SF-36) bodily pain and physical function scores  (100-
point scales, with higher scores indicating less severe symptoms) and the modified 
Oswestry Disability Index (100-point scale, with lower scores indicating less severe 
symptoms) at 6 weeks, 3 months, 6 months, 1 year, and 2 years.
RESULTS
We enrolled 304 patients in the randomized cohort and 303 in the observational co-
hort. The baseline characteristics of the two cohorts were similar. The one-year cross-
over rates were high in the randomized cohort (approximately 40% in each direction) 
but moderate in the observational cohort (17% crossover to surgery and 3% crossover 
to nonsurgical care). The intention-to-treat analysis for the randomized cohort showed 
no statistically significant effects for the primary outcomes. The as-treated analysis 
for both cohorts combined showed a significant advantage for surgery at 3 months 
that increased at 1 year and diminished only slightly at 2 years. The treatment effects 
at 2 years were 18.1 for bodily pain (95% confidence interval [CI], 14.5 to 21.7), 18.3 
for physical function (95% CI, 14.6 to 21.9), and −16.7 for the Oswestry Disability Index 
(95% CI, −19.5 to −13.9). There was little evidence of harm from either treatment.
CONCLUSIONS
In nonrandomized as-treated comparisons with careful control for potentially con-
founding baseline factors, patients with degenerative spondylolisthesis and spinal 
stenosis treated surgically showed substantially greater improvement in pain and func-
tion during a period of 2 years than patients treated nonsurgically. (ClinicalTrials.
gov number, NCT00000409.)
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Degenerative spondylolisthesis is the slipping forward of one lumbar verte-bra on another with an intact neural arch. 
It rarely occurs before the age of 50 years, and it 
disproportionately affects women, particularly 
black women, with a male:female ratio of approx-
imately 1:6.1 Slippage most commonly occurs at 
the L4–L5 level and rarely exceeds 30% of verte-
bral width.1 Degenerative spondylolisthesis is gen-
erally asymptomatic, but it can be associated with 
symptomatic spinal stenosis.1
Spinal stenosis, the most common reason for 
lumbar surgery in adults over the age of 65, is a 
narrowing of the spinal canal with encroachment 
on the neural structures by surrounding bone and 
soft tissue. Patients typically present with neuro-
genic claudication — pain in the buttocks or legs 
with walking or standing that resolves with sitting 
or lumbar f lexion. However, anatomical spinal 
stenosis is frequently detected by imaging studies 
in asymptomatic patients; thus, clinical correlation 
between symptoms and imaging is critical.2
Two studies have compared surgery with non-
surgical treatment for spinal stenosis, but both of 
these studies included patients with and those 
without degenerative spondylolisthesis.3-5 Several 
studies have compared surgical techniques in co-
horts with degenerative spondylolisthesis; how-
ever, these studies had small samples with limited 
geographic participation and lacked nonsurgical 
controls and validated outcome measures.6-8 The 
optimal treatment strategy for symptomatic de-
generative spondylolisthesis remains unclear.
The Spine Patient Outcomes Research Trial 
(SPORT) was designed to compare the effective-
ness of surgical and nonsurgical treatment among 
participants with confirmed diagnoses of inter-
vertebral disk herniation,9,10 spinal stenosis, and 
degenerative spondylolisthesis.11 Here we report 
the 2-year outcomes of patients with degenerative 
spondylolisthesis.
Me thods
Study Design
The SPORT was conducted in 11 states at 13 med-
ical centers in the United States that have multi-
disciplinary spine practices. The SPORT included 
both a randomized cohort and a concurrent obser-
vational cohort with identical selection criteria and 
outcomes assessment.12 The standardized proto-
col was approved by human subjects committees 
at each participating institution, and an indepen-
dent data and safety monitoring board monitored 
the results of the trial. The principal investigator 
had full access to all the data in the study and takes 
responsibility for the accuracy and integrity of the 
data analysis. Additional background information 
has been published previously.9-11,13
Patient Population
All patients had neurogenic claudication or radic-
ular leg pain with associated neurologic signs, spi-
nal stenosis shown on cross-sectional imaging, 
and degenerative spondylolisthesis shown on lat-
eral radiographs obtained with the patient in a 
standing position. The patients had had persistent 
symptoms for at least 12 weeks and had been con-
firmed as surgical candidates by their physicians. 
Patients with adjacent levels of stenosis were eli-
gible; patients with spondylolysis and isthmic 
spondylolisthesis were not. The nature of non-
surgical care before enrollment was not prespec-
ified but included physical therapy in 68% of pa-
tients, epidural injections in 55%, chiropractic 
treatment in 25%, antiinflammatory agents in 
63%, and opioid analgesic agents in 30%.
Research nurses at each site identified poten-
tial participants and verified their eligibility. The 
patients were offered enrollment in either cohort 
and gave written informed consent after viewing 
videotapes explaining the expected benefits, risks, 
and uncertainties of the treatments.14,15 Partici-
pants in the randomized cohort received computer-
generated random treatment assignments blocked 
according to center; those in the observational 
cohort chose their treatment with their physician. 
Enrollment began in March 2000 and ended in 
February 2005.
Study Interventions
The protocol surgery consisted of a standard pos-
terior decompressive laminectomy with or with-
out bilateral single-level fusion (iliac crest bone 
grafting with or without posterior pedicle-screw 
instrumentation).11 The nonsurgical protocol was 
usual care, recommended to include at least active 
physical therapy, education or counseling includ-
ing instructions for exercising at home, and non-
steroidal antiinflammatory agents if tolerated.11,13
Study Measures
The primary end points were the Medical Outcomes 
Study 36-Item Short-Form General Health Survey 
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(SF-36) bodily pain and physical function scores16-19 
and the Oswestry Disability Index (American Acad-
emy of Orthopaedic Surgeons/Modems version)20 
measured at 6 weeks and at 3, 6, 12, and 24 months 
after enrollment. Secondary outcomes included 
patient-reported improvement, satisfaction with 
current symptoms and care,21 the Stenosis Bother-
someness Index,22,23 and the Low Back Pain 
Bothersomeness Scale.3 The SF-36 scores range 
from 0 to 100, with higher scores indicating less 
severe symptoms; the Oswestry Disability Index 
ranges from 0 to 100, with lower scores indicat-
ing less severe symptoms; the Stenosis Bother-
someness Index ranges from 0 to 24, with lower 
scores indicating less severe symptoms; and the 
Low Back Pain Bothersomeness Scale ranges from 
0 to 6, with lower scores indicating less severe 
symptoms.
Statistical Analysis
A sample size of 150 patients in each treatment 
group for the randomized cohort was determined 
as sufficient on the basis of a two-sided t-test with 
a power of 0.85 to detect a 10-point difference in 
the SF-36 bodily pain and physical function scores 
or a similar effect size in the Oswestry Disability 
Index. The sample size allowed for up to 20% of 
the data to be missing but did not account for any 
specific levels of nonadherence.
Initial analyses compared baseline character-
istics of the patients between the randomized co-
hort and the observational cohort and between 
the treatment groups of the combined random-
ized cohort and the observational cohort. The ex-
tent of missing data and the percentage of patients 
undergoing surgery were calculated for each 
scheduled follow-up. Baseline predictors of time 
until surgical treatment in both cohorts (including 
treatment crossovers) were determined by a step-
wise proportional-hazards regression model with 
an inclusion criterion of P<0.1 to enter and P>0.05 
to exit. Predictors of missing follow-up visits at 
1 year were determined by stepwise logistic re-
gression with entry and exit criteria of P<0.1 and 
P>0.05, respectively.
Primary analyses compared surgical and non-
surgical treatments using changes from baseline 
at each follow-up time for SF-36 bodily pain and 
physical function and for the Oswestry Disability 
Index. The randomized cohort was initially ana-
lyzed on an intention-to-treat basis. However, be-
cause of the extent of crossover, subsequent analy-
ses combined the randomized cohort and the 
observational cohort and were based on treatments 
actually received. In these as-treated analyses, the 
treatment indicator was a time-varying covariate, 
allowing for variable times to surgery. Before the 
time of surgery, all changes from baseline were 
included in the estimates of the nonsurgical treat-
ment effect. After surgery, subsequent changes in 
outcomes were assigned to the surgical group with 
follow-up measured from the date of surgery. The 
randomized cohort and the observational cohort 
were each analyzed to produce separate as-treated 
estimates of treatment effect. These results were 
compared with the use of a Wald test to simul-
taneously test all follow-up visit times for differ-
ences in estimated treatment effects between the 
randomized and observational groups.24 Subse-
quent analyses combined the two cohorts.
To adjust for potential confounding effects, 
baseline variables associated with missing data 
or treatment received were included as covariates 
in longitudinal regression models.24 A random 
effect was specified to account for the correla-
tion between the repeated measurements of in-
dividual patients. Computations were performed 
with the use of SAS software (PROC MIXED for 
continuous data with normal random effects and 
PROC GENMOD for binary and non-normal sec-
ondary outcomes). Statistical significance was de-
fined as P<0.05 on the basis of a two-sided hypoth-
esis test (SAS software, version 9.1). Data for these 
analyses were collected through October 3, 2006.
R esult s
Overall, 607 of 892 eligible participants were en-
rolled in the SPORT (304 in the randomized co-
hort and 303 in the observational cohort). A total 
of 601 patients (99%) completed at least one fol-
low-up visit and were included in the analysis; 
between 83% and 95% of enrollees supplied data 
at each follow-up visit (Fig. 1).
In the randomized cohort, 159 patients were 
assigned to surgery and 145 to nonsurgical treat-
ment. Of those assigned to surgery, 57% under-
went surgery by 1 year and 64% by 2 years. In 
the group assigned to nonsurgical care, 44% un-
derwent surgery by 1 year and 49% by 2 years. In 
the observational cohort, 173 patients initially 
chose surgery and 130 initially chose nonsurgical 
care. Of those initially choosing surgery, 97% un-
derwent surgery by 1 year, and one additional pa-
The New England Journal of Medicine 
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39p6
892 Patients were eligible
1164 Patients were screened
272 Patients were ineligible
124 Were not surgical candidates
40 Had inadequate nonsurgical treatment
29 Had fracture, infection, or deformity
19 Had cancer
60 Had other reasons
285 Patients declined to participate
304 Were in the randomized
cohort
303 Were in the observational
cohort
159 Were assigned
to surgery
145 Were assigned to
nonsurgical treatment
146 Were available at 6 wk
12 Missed the follow-up visit
1 Withdrew
0 Died
15 (9%) Underwent surgery
135 Were available at 6 wk
9 Missed the follow-up visit
1 Withdrew
0 Died
11 (8%) Underwent surgery
155 Were available at 6 wk
17 Missed the follow-up visit
1 Withdrew
0 Died
119 (69%) Underwent surgery
124 Were available at 6 wk
6 Missed the follow-up visit
0 Withdrew
0 Died
0 Underwent surgery
173 Chose surgery
130 Chose nonsurgical
treatment
144 Were available at 3 mo
13 Missed the follow-up visit
2 Withdrew
0 Died
57 (36%) Underwent surgery
133 Were available at 3 mo
11 Missed the follow-up visit
1 Withdrew
0 Died
35 (24%) Underwent surgery
160 Were available at 3 mo
11 Missed the follow-up visit
2 Withdrew
0 Died
153 (88%) Underwent surgery
114 Were available at 3 mo
14 Missed the follow-up visit
2 Withdrew
0 Died
3 (2%) Underwent surgery
146 Were available at 6 mo
10 Missed the follow-up visit
2 Withdrew
1 Died
84 (53%) Underwent surgery
134 Were available at 6 mo
9 Missed the follow-up visit
1 Withdrew
1 Died
55 (38%) Underwent surgery
161 Were available at 6 mo
10 Missed the follow-up visit
2 Withdrew
0 Died
165 (95%) Underwent surgery
115 Were available at 6 mo
9 Missed the follow-up visit
5 Withdrew
1 Died
9 (7%) Underwent surgery
144 Were available at 1 yr
9 Missed the follow-up visit
4 Withdrew
2 Died
91 (57%) Underwent surgery
134 Were available at 1 yr
8 Missed the follow-up visit
2 Withdrew
1 Died
64 (44%) Underwent surgery
162 Were available at 1 yr
8 Missed the follow-up visit
3 Withdrew
0 Died
167 (97%) Underwent surgery
117 Were available at 1 yr
3 Missed the follow-up visit
8 Withdrew
2 Died
22 (17%) Underwent surgery
132 Were available at 2 yr
8 Missed the follow-up visit
11 Withdrew
2 Died
6 Visit pending
101 (64%) Underwent surgery
120 Were available at 2 yr
6 Missed the follow-up visit
5 Withdrew
5 Died
9 Visit pending
71 (49%) Underwent surgery
159 Were available at 2 yr
6 Missed the follow-up visit
5 Withdrew
3 Died
168 (97%) Underwent surgery
110 Were available at 2 yr
6 Missed the follow-up visit
11 Withdrew
3 Died
32 (25%) Underwent surgery
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Figure 1. Exclusion, Enrollment, Randomization, and Follow-up of Trial Participants.
The values are cumulative over 2 years. For example, a total of two patients in the group assigned to surgery died during the 2-year  
follow-up period.
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tient underwent surgery between 1 and 2 years 
from the time of enrollment. Of those initially 
choosing nonsurgical treatment, 17% underwent 
surgery by 1 year and 25% by 2 years. In both co-
horts combined, 372 patients underwent surgery 
within the first 2 years and 235 received only non-
surgical treatment.
Patient Characteristics
Table 1 shows the baseline characteristics and 
clinical findings of participants in the random-
ized and the observational cohorts. The cohorts 
were remarkably similar; however, patients in the 
observational cohort had more L4–L5 involve-
ment, less involvement of L3–L4, and less lateral 
recess stenosis.
Summary statistics for the combined cohorts 
are also shown in Table 1 according to treatment 
received; the mean age was 66 years. Eighty-five 
percent of patients had neurogenic claudication, 
and 77% had associated dermatomal pain radia-
tion. Most of the degenerative slips and associated 
stenoses were at L4–L5. On imaging, stenosis was 
graded as severe in 60% of patients, and 35% had 
multiple levels of stenosis.
At baseline, patients in the group undergoing 
surgery from the combined randomized and ob-
servational cohorts were younger and more likely 
to be receiving compensation (e.g., workers’ com-
pensation or social security) than those receiving 
nonsurgical treatment. They had worse pain, func-
tion, disability, and symptoms than patients in 
the nonsurgical group. Patients in the surgery 
group were more dissatisfied with their symp-
toms and at enrollment more often rated their 
symptoms as worsening. This observation high-
lights the need to control for baseline differences 
in the adjusted models. The final model controlled 
for the following covariates, selected as described 
in the Methods section: age, sex, work status, de-
pression, osteoporosis, joint problems, duration of 
current symptoms, reflex deficit, number of mod-
erate or severe stenotic levels, baseline score (for 
the SF-36, the Oswestry Disability Index, and the 
Stenosis Bothersomeness Index), and the center 
where the patient was treated. SF-36 and the Os-
westry Disability Index scores were also adjusted 
for the baseline Stenosis Bothersomeness Index 
score.
Lateral radiographs obtained with the patient 
in a neutral standing position were available for 
independent review for 169 patients. The percent-
age of slip as measured by the method of Mor-
gan and King25 ranged from 1 to 37% (median, 
15%; interquartile range, 10 to 21%). Eighty-six 
percent of patients had grade 1 slip and 14% had 
grade 2.
Nonsurgical Treatments
Nonsurgical treatments used during the SPORT 
included physical therapy (42%), epidural steroid 
injections (45%), nonsteroidal antiinflammatory 
drugs (51%), and opioids (34%). Nonsurgical treat-
ments were similar in the randomized cohort and 
the observational cohort, though more patients 
in the randomized cohort reported visits to a sur-
geon (44% vs. 34%, P = 0.04), receiving injections 
(49% vs. 37%, P = 0.02), and narcotics use (40% vs. 
26%, P = 0.007).
Surgical Treatment and Complications
The median surgical time was 199 minutes, with 
a mean blood loss of 589 ml (Table 2). There were 
no significant differences between the cohorts in 
rates of intraoperative blood replacement, but there 
was a difference in the postoperative transfusion 
rates (16% in the randomized cohort vs. 26% in 
the observational cohort, P = 0.04). The most com-
mon surgical complication was dural tear (10%). 
The 2-year reoperation rate was 12%.
Main Treatment effects
The intention-to-treat analysis of the randomized 
cohort showed no statistically significant effects 
for the primary outcomes, on the basis of a global 
hypothesis test for differences in mean changes 
from baseline between the treatment groups in-
cluding all time periods. Treatment effects at 
2 years were 1.5 for SF-36 bodily pain (95% con-
fidence interval [CI], –4.2 to 7.3; P = 0.52), 1.9 for 
physical function (95% CI, –3.7 to 7.5; P = 0.71), 
and 2.2 for the Oswestry Disability Index (95% CI, 
–2.3 to 6.8; P = 0.68). 
As-treated effects for the combined cohorts 
were statistically significant in favor of surgery for 
all primary and secondary outcomes (Table 3 and 
Fig. 2). Treatment effects were stable for 2 years 
and were significant for all time periods, with 
treatment effects at 2 years of 18.1 for SF-36 
bodily pain (95% CI, 14.5 to 21.7), 18.3 for physical 
function (95% CI, 14.6 to 21.9), and −16.7 for the 
Oswestry Disability Index (95% CI, −19.5 to −13.9). 
The results of the intention-to-treat and the as-
treated analyses of the randomized and the ob-
servational cohorts are compared in Figure 2. The 
as-treated treatment effects at 2 years were nearly 
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Table 1. Characteristics of the Patients According to Study Cohort at Baseline.*
Characteristic
Randomized  
Cohort 
(N = 301)
Observational 
Cohort 
(N = 300)
P  
Value
Surgical 
Treatment
(N = 368)†
Nonsurgical 
Treatment
(N = 233)†
P 
Value
Age — yr 66.0±10.0 66.1±10.6 0.86 64.7±10.1 68.2±10.3 <0.001
Female sex — no. (%) 200 (66) 212 (71) 0.30 255 (69) 157 (67) 0.69
Race or ethnic group — no. (%)‡
Non-Hispanic 292 (97) 295 (98) 0.42 359 (98) 228 (98) 0.97
White 259 (86) 247 (82) 0.26 316 (86) 190 (82) 0.19
Black 29 (10) 32 (11) 0.78 30 (8) 31 (13) 0.06
Any college education — no. (%) 201 (67) 199 (66) 0.98 247 (67) 153 (66) 0.78
Married — no. (%) 198 (66) 198 (66) 0.98 249 (68) 147 (63) 0.29
Work status — no. (%) 0.42 0.96
Working full- or part-time 116 (39) 102 (34) 133 (36) 85 (36)
Disabled 21 (7) 30 (10) 33 (9) 18 (8)
Retired 129 (43) 128 (43) 156 (42) 101 (43)
Other 35 (12) 40 (13) 46 (12) 29 (12)
Compensation — no. (%)§ 21 (7) 20 (7) 0.99 34 (9) 7 (3) 0.005
Body-mass index¶ 29.1±5.7 29.2±6.7 0.91 29.4±6.5 28.8±5.7 0.22
Current smoker — no. (%) 23 (8) 28 (9) 0.55 34 (9) 17 (7) 0.49
Coexisting conditions — no. (%)
Hypertension 141 (47) 134 (45) 0.65 164 (45) 111 (48) 0.51
Diabetes 39 (13) 41 (14) 0.89 48 (13) 32 (14) 0.90
Osteoporosis 33 (11) 36 (12) 0.79 40 (11) 29 (12) 0.65
Heart problem 61 (20) 61 (20) 0.94 65 (18) 57 (24) 0.055
Stomach problem 64 (21) 69 (23) 0.68 79 (21) 54 (23) 0.70
Bowel or intestinal problem 17 (6) 26 (9) 0.20 30 (8) 13 (6) 0.30
Depression 56 (19) 42 (14) 0.16 63 (17) 35 (15) 0.57
Joint problem 175 (58) 169 (56) 0.72 202 (55) 142 (61) 0.17
Other‖ 121 (40) 113 (38) 0.58 146 (40) 88 (38) 0.70
Symptom duration >6 mo — no. (%) 185 (61) 176 (59) 0.54 227 (62) 134 (58) 0.35
SF-36 scores**
Bodily pain 30.7±16.4 31.7±17.5 0.44 29.2±16.8 34.4±16.7 <0.001
Physical function 34.4±21.5 34.3±23.3 0.98 30.5±20.5 40.3±23.9 <0.001
Mental component summary 49.9±11.9 50.5±11.2 0.53 49.5±11.6 51.3±11.3 0.06
Oswestry Disability Index†† 41.8±16.5 41.3±19.1 0.72 45.0±16.6 36.2±18.5 <0.001
Stenosis Frequency Index‡‡ 14.2±5.5 13.8±5.7 0.36 14.8±5.5 12.6±5.4 <0.001
Stenosis Bothersomeness Index§§ 14.8±5.6 14.6±5.6 0.79 15.6±5.5 13.3±5.4 <0.001
Low Back Pain Bothersomeness Scale¶¶ 4.3±1.8 4.3±1.8 0.99 4.4±1.8 4.0±1.9 0.01
Very dissatisfied with symptoms — no. (%) 203 (67) 213 (71) 0.39 287 (78) 129 (55) <0.001
Self-assessment of health trend — no. (%)‖‖ 0.73 <0.001
Problem getting better 17 (6) 21 (7) 17 (5) 21 (9)
Problem staying about the same 100 (33) 94 (31) 89 (24) 105 (45)
Problem getting worse 179 (59) 182 (61) 258 (70) 103 (44)
Treatment preference at baseline — no. (%)*** <0.001 <0.001
Definitely prefer nonsurgical treatment 44 (15) 83 (28) 32 (9) 95 (41)
Probably prefer nonsurgical treatment 71 (24) 37 (12) 40 (11) 68 (29)
Not sure 117 (39) 20 (7) 83 (23) 54 (23)
Probably prefer surgery 30 (10) 31 (10) 51 (14) 10 (4)
Definitely prefer surgery 38 (13) 129 (43) 162 (44) 5 (2)
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Table 1. (Continued.)
Characteristic
Randomized 
Cohort 
(N = 301)
Observational 
Cohort 
(N = 300)
P
Value
Surgical  
Treatment  
(N = 368)†
Nonsurgical  
Treatment  
(N = 233)†
P
Value
Pseudoclaudication — no. (%) 259 (86) 252 (84) 0.56 319 (87) 192 (82) 0.19
Straight-leg–raising test or femoral-tension 
sign — no. (%)
44 (15) 41 (14) 0.83 48 (13) 37 (16) 0.39
Dermatomal pain radiation — no. (%) 239 (79) 229 (76) 0.42 288 (78) 180 (77) 0.85
Any neurologic deficit — no. (%) 142 (47) 152 (51) 0.44 185 (50) 109 (47) 0.45
Asymmetric reflex depression 53 (18) 40 (13) 0.18 65 (18) 28 (12) 0.08
Asymmetric sensory decrease 79 (26) 90 (30) 0.35 108 (29) 61 (26) 0.45
Asymmetric motor weakness 74 (25) 72 (24) 0.94 87 (24) 59 (25) 0.71
Listhesis level — no. (%) 0.17 0.69
L3–L4 34 (11) 23 (8) 33 (9) 24 (10)
L4–L5 267 (89) 277 (92) 335 (91) 209 (90)
Stenosis level — no. (%)
L2–L3 31 (10) 22 (7) 0.26 33 (9) 20 (9) 0.99
L3–L4 136 (45) 100 (33) 0.004 145 (39) 91 (39) 1.00
L4–L5 285 (95) 295 (98) 0.03 357 (97) 223 (96) 0.54
L5–S1 27 (9) 30 (10) 0.77 29 (8) 28 (12) 0.12
No. of moderate or severe stenotic levels — 
no. (%)
0.10 0.14
0 7 (2) 16 (5) 9 (2) 14 (6)
1 179 (59) 191 (64) 231 (63) 139 (60)
2 96 (32) 76 (25) 104 (28) 68 (29)
≥3 19 (6) 17 (6) 24 (7) 12 (5)
Stenosis location — no. (%)
Central 277 (92) 272 (91) 0.65 341 (93) 208 (89) 0.20
Lateral recess 286 (95) 260 (87) <0.001 338 (92) 208 (89) 0.36
Neuroforamen 123 (41) 120 (40) 0.89 152 (41) 91 (39) 0.64
Stenosis severity — no. (%) 0.08 0.08
Mild 7 (2) 16 (5) 9 (2) 14 (6)
Moderate 116 (39) 99 (33) 131 (36) 84 (36)
Severe 178 (59) 185 (62) 228 (62) 135 (58)
Instability — no. (%)††† 26 (9) 21 (7) 0.55 35 (10) 12 (5) 0.07
* Plus–minus values are means ±SD. 
† Patients in the two cohorts combined were classified according to whether they received surgical treatment or only 
nonsurgical treatment during the first 2 years of enrollment.
‡ Race or ethnic group was self-assessed. Whites and blacks could be either Hispanic or non-Hispanic.
§ This category includes patients who were receiving or had applications pending for workers’ compensation, Social 
 Security compensation, or other compensation.
¶ The body-mass index is the weight in kilograms divided by the square of the height in meters.
‖ Other problems included those related to stroke, cancer, lung disease, fibromyalgia, chronic fatigue syndrome, post-
traumatic stress disorder, alcohol abuse, drug dependency, liver disease, kidney disease, vascular disease, neurologic 
disease, migraine, or anxiety.
** The SF-36 scores range from 0 to 100, with higher scores indicating less severe symptoms.
†† The Oswestry Disability Index ranges from 0 to 100, with lower scores indicating less severe symptoms.
‡‡ The Stenosis Frequency Index ranges from 0 to 24, with lower scores indicating less severe symptoms.
§§ The Stenosis Bothersomeness Index ranges from 0 to 24, with lower scores indicating less severe symptoms.
¶¶ The Low Back Pain Bothersomeness Scale ranges from 0 to 6, with lower scores indicating less severe symptoms.
‖‖ Data were not available for eight patients.
*** Data were not available for one patient.
††† Instability is defined as a change of more than 10 degrees of angulation or more than 4 mm of translation of the ver-
tebrae between flexion and extension of the spine.
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identical in the randomized and the observational 
cohorts. For SF-36 bodily pain, the effect was 17.8 
(95% CI, 12.5 to 23.0) in the randomized cohort 
as compared with 18.5 (95% CI, 13.4 to 23.6) in 
the observational cohort; for SF-36 physical func-
tion, the effect was 16.7 (95% CI, 11.4 to 22.1) 
in the randomized cohort as compared with 19.9 
(95% CI, 14.8 to 24.9) in the observational cohort; 
and for the Oswestry Disability Index, the effect 
was −15.9 (95% CI, −20.2 to −11.7) in the random-
ized cohort as compared with −17.7 (95% CI, −21.6 
to −13.7) in the observational cohort. The global 
hypothesis test comparing the treatment effects 
in the randomized and the observational cohorts 
over all time periods revealed no significant dif-
ference between the cohorts: P = 0.29 for SF-36 
bodily pain, P = 0.28 for SF-36 physical function, 
and P = 0.97 for the Oswestry Disability Index. 
Subgroup Analyses
Models fitted for selected subgroups were exam-
ined for evidence of modification of treatment 
efficacy. Participants less than 65 years old at 
baseline had larger treatment effects in favor of 
surgery at 3 months (21.3 vs. 14.6 for bodily pain, 
P = 0.02) but not at 1 or 2 years. The treatment 
effect for a degenerative spondylolisthesis level of 
L3–L4 was larger than that for a level of L4–L5 
(33.1 vs. 16.8 for SF-36 bodily pain, P = 0.01) at 
2 years but not at 3 months or 1 year. Participants 
with no more than a high-school education had 
smaller treatment effects for surgery at 3 months 
(12.8 vs. 20.5 for SF-36 bodily pain, P = 0.02) and 
2 years (11.5 vs. 21.6 for SF-36 bodily pain, 
P = 0.01). Other subgroups (defined according to 
sex, smoking history, severity of symptoms at base-
line, duration of symptoms, treatment preference, 
Table 2. Surgical Treatments and Complications.*
Variable
Randomized  
Cohort  
(N = 172)
Observational  
Cohort 
(N = 200) P Value
Specific procedure — no. (%)† 0.92
Decompression only 10 (6) 10 (5)
Fusion without instrumentation 35 (21) 43 (21)
Fusion with instrumentation‡ 123 (73) 147 (74)
Multilevel fusion — no. (%) 46 (27) 40 (20) 0.13
Decompression level — no. (%) 
L2–L3 25 (15) 17 (8) 0.08
L3–L4 92 (54) 84 (42) 0.02
L4–L5 165 (98) 190 (95) 0.34
L5–S1 60 (36) 47 (24) 0.01
No. of levels decompressed — no. of patients (%) 0.01
0 1 (1) 2 (1)
1 56 (33) 98 (49)
2 65 (38) 65 (32)
≥3 47 (28) 35 (18)
Operation time — min 210.5±81.7 202.7±85.8 0.37
Blood loss — ml 570.0±425.7 606.2±511.2 0.47
Blood replacement — no. (%) 
Intraoperative replacement 60 (36) 67 (34) 0.71
Postoperative transfusion 27 (16) 51 (26) 0.04
Length of hospital stay — days 6.9±28.7 4.8±3.3 0.30
Intraoperative complications — no. (%)§
Dural tear or cerebrospinal fluid leak 19 (11) 18 (9) 0.59
Vascular injury 1 (1) 0 0.93
Other 3 (2) 6 (3) 0.67
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number of stenotic levels, severity of stenosis on 
imaging, number of coexisting conditions, and 
baseline SF-36 mental component summary score) 
did not show significant effect modification. 
These results should be considered cautiously, be-
cause the study was not designed or powered to 
examine subgroup differences.
Discussion
In patients with image-confirmed degenerative 
spondylolisthesis and symptoms persisting for at 
least 12 weeks, the intention-to-treat analysis 
found no significant advantage for surgery over 
nonsurgical care, but the analysis was severely 
limited by treatment crossover. As-treated analy-
ses showed that surgery was superior to nonsur-
gical treatment in relieving symptoms and im-
proving function. This treatment effect was seen 
as early as at the 6-week follow-up and persisted 
over 2 years. The nonsurgical-treatment group 
showed only moderate improvement over time. 
The smaller treatment effect for surgery seen in 
less-educated subjects is intriguing but unex-
plained and may be a chance finding in a post hoc 
subgroup.
The randomized and observational cohorts 
were remarkably similar at baseline. The only 
significant differences were small ones in level 
and location of stenosis on baseline imaging. The 
cohorts also had similar outcomes, with no sig-
nificant differences between the treatment effects 
in the as-treated analyses. These similarities sup-
port the validity of the combined analysis pre-
sented here.
There was little evidence of harm from either 
Table 2. (Continued.)
Variable
Randomized 
Cohort 
(N = 172)
Observational  
Cohort  
(N = 200) P Value
Postoperative complications and events — no. (%)¶
Nerve-root injury 1 (1) 0 0.93
Wound dehiscence 0 1 (1) 0.93
Wound hematoma 0 1 (1) 0.93
Wound infection 8 (5) 3 (2) 0.12
Other 21 (12) 14 (7) 0.10
Death within 3 mo after surgery — no. (%) 1 (1) 1 (1) 0.55
Additional spine surgeries within 1 yr — no. (%)‖** 13 (8) 11 (6) 0.40
Recurrent stenosis or progressive listhesis 1 (1) 1 (1)
Pseudarthrosis or fusion exploration 0 1 (1)
Complication 11 (6) 7 (4)
New condition 1 (1) 1 (0.5)
Additional spine surgeries within 2 yr — no. (%)‖ 18 (11) 23 (12) 0.84
Recurrent stenosis or progressive listhesis 5 (3) 5 (2)
Pseudarthrosis or fusion exploration 0 3 (2)
Complication 13 (8) 11 (6)
New condition‖ 1 (1) 4 (2)
* A total of 172 patients in the randomized cohort and 200 patients in the observational cohort underwent surgery with-
in 2 years after enrollment. Information about the surgery was available for 169 patients from the randomized cohort 
and 200 from the observational cohort. Plus–minus values are means ±SD.
† Data on specific procedures were available for 168 patients in the randomized cohort and 200 patients in the observa-
tional cohort.
‡ All 270 patients undergoing fusion with instrumentation had pedicle screws; 46 underwent additional interbody fusion.
§ No cases were reported of aspiration into the respiratory tract, nerve-root injury, or operation at the wrong level.
¶ Complications or events occurring up to 8 weeks after surgery are listed. There were no reported cases of bone-graft 
complication, cerebrospinal fluid leak, paralysis, cauda equina injury, or pseudarthrosis.
‖ The postsurgical reoperation rates are Kaplan–Meier estimates.
** One new stenosis occurred in the randomized cohort, and two new herniations and two new stenoses occurred in the 
observational cohort.
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treatment. Often patients fear they will get worse 
without surgery, but the patients receiving non-
surgical treatment, on average, showed moderate 
improvement in all outcomes. No patients under-
going surgical or nonsurgical treatment had cauda 
equina syndrome; 89% of surgical patients had 
no operative complications.
The characteristics of the participants in the 
SPORT were similar to those in previous studies 
of degenerative spondylolisthesis and mixed co-
horts of patients with stenosis. The mean age of 
66 years was similar to that in the cohorts re-
ported by Herkowitz and Kurz8 (63.5 years), 
Fischgrund et al.7 (67 years), the Maine Lumbar 
Spine Study (MLSS)3 (66 years), Yukawa et al.26 
(63 years), and Malmivaara et al.5 (63 years). At 
enrollment, 60% of the SPORT participants re-
ported having had symptoms for more than 
6 months, as did 60% of the participants in the 
MLSS. Baseline functional status in the SPORT 
was similar to that in the MLSS (mean SF-36 
physical function scores, 34 and 35, respectively) 
and in the randomized trial by Malmivaara et al. 
(mean Oswestry Disability Index scores, 41.5 and 
35.0, respectively).
The surgical outcomes in the SPORT were gen-
erally similar to those in previous surgical series. 
Herkowitz and Kurz8 reported absolute improve-
ments of 33% for back pain and 55% for leg pain 
(6-point scales) at 3 years, similar to the changes 
of 31% and 41%, respectively (7-point scales), seen 
in the SPORT at 2 years. Also, the improvement 
at 1 year in the patients in the SPORT who were 
undergoing surgery for degenerative spondylolis-
thesis was similar to the outcomes of surgery in 
the MLSS mixed-stenosis (those with and those 
without degenerative spondylolisthesis) cohort. 
The improvement in the SF-36 bodily pain score 
was 32 in the SPORT and 43 in the MLSS, and 
the improvement in the SF-36 physical function 
score was 29 in the SPORT and 27 in the MLSS.3
The nonsurgical outcomes in the SPORT were 
similar to those in the study by Malmivaara et al.5 
and in the MLSS.3 Malmivaara et al. reported 
absolute improvements in back pain at 2 years of 
18% on an 11-point scale, as compared with 17% 
on a 7-point scale in the SPORT, and an improve-
ment in leg pain of 16%, as compared with 17% 
in the SPORT. Similarly, at 1 year the MLSS re-
ported an improvement of 12.0 points in SF-36 
bodily pain, as compared with 12.7 in the SPORT. 
The nonsurgical functional outcomes, however, 
were better in the SPORT than in these previous 
studies. SF-36 physical function improved by 9.6 
points in the SPORT nonsurgical group, as com-
pared with 1.0 point in the MLSS, and the Os-
westry Disability Index improved by −7.5 points 
in the SPORT, as compared with −4.5 points in 
the study by Malmivaara et al. The somewhat 
greater improvement in the SPORT may be related 
to the nonsurgical treatments received. The SPORT 
participants had higher rates of epidural steroid 
injections than did the MLSS participants (44% 
vs. 18%), similar rates of physical therapy, and 
much lower use of activity restriction (16% vs. 
29%) and transcutaneous electrical nerve stimu-
lation (2% vs. 14%). Differences in nonsurgical 
outcomes might also be due to differences in the 
underlying disease process in patients with de-
generative spondylolisthesis as compared with a 
mixed stenosis population in the study by Malmi-
vaara et al. and in the MLSS.
We can directly compare estimates of treatment 
effect in the SPORT with those in the MLSS and 
the study by Malmivaara et al. The estimated 1-year 
treatment effects for surgery in the SPORT were 
smaller than those in the MLSS (18.8 vs. 30.4 
points for SF-36 bodily pain, and 19.4 vs. 25.5 
points for SF-36 physical function). However, the 
MLSS did not adjust treatment effects for base-
line differences between the treatment groups, 
which probably explains these discrepancies. The 
estimated 1-year treatment effects were similar 
in the SPORT and in the study by Malmivaara et al. 
(Oswestry Disability Index, −17.9 vs. −11.3, re-
spectively; leg pain, 23% [7-point scale] vs. 15% 
[11-point scale], respectively; and back pain, 20% 
[7-point scale] vs. 21% [11-point scale], respec-
tively.
The 1-year rate of reoperation for recurrent 
stenosis or spondylolisthesis was 0.6%, less than 
the rates reported by Malmivaara et al. (2%) and 
the MLSS (1.2%). The reoperation rate increased 
to 3% at 2 years. The perioperative mortality rate 
was 0.6%, which is less than the 1.3% seen in 
Medicare patients after fusion surgery for spon-
dylolisthesis.27 The 2-year mortality rate was simi-
lar in both treatment groups and less than actu-
arial projections.
A limitation of this study is the marked de-
gree of nonadherence to randomized treatment. 
The protocol stipulated that patients assigned to 
surgery have their surgery within 3 to 6 months 
after enrollment, a period thought to be appro-
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priate in the clinical experience of the investiga-
tors. Although patients consented to this proto-
col, as in all clinical trials this consent could be 
changed at the request of the patient, and many 
chose to do so. This reduced the power of the 
intention-to-treat analysis to demonstrate a treat-
ment effect. Although the as-treated analysis lost 
the strong protection from confounding conferred 
by randomization, these analyses were carefully 
controlled for important covariates and yielded 
results similar to previous studies.
Another limitation is the heterogeneity of the 
treatment interventions. The choice of nonsurgi-
cal therapies was at the discretion of the treating 
physician and the patient. However, with limited 
evidence regarding efficacy for most nonsurgical 
treatments for degenerative spondylolisthesis, 
creating a fixed protocol for nonsurgical treat-
ment was neither clinically feasible nor general-
izable. The nonsurgical treatments used were 
consistent with published guidelines.28,29 Simi-
larly, the surgeries performed varied in terms of 
the presence, method, and extent of spinal fusion 
accompanying the decompression. We cannot 
make direct conclusions regarding the compari-
son between the effect of surgery and any specific 
nonsurgical treatment, nor do we directly com-
pare the efficacy of nonsurgical treatment with 
one specific surgical technique.
The magnitudes of the mean changes reported 
here after surgery for degenerative spondylolis-
thesis are less than those reported for patients in 
a SPORT observational cohort undergoing surgery 
for intervertebral disk herniation. The mean change 
scores after 2 years were as follows: SF-36 bodily 
pain, 29.9 for degenerative spondylolisthesis ver-
sus 42.6 for intervertebral disk herniation; SF-36 
physical function, 26.7 for degenerative spondy-
lolisthesis versus 43.9 for intervertebral disk her-
niation; Oswestry Disability Index, −24.2 for 
degenerative spondylolisthesis versus 37.6 for in-
tervertebral disk herniation.9,10 However, the treat-
ment effects for surgery in the degenerative-
spondylolisthesis group were larger than those 
in the study of intervertebral disk herniation (18.4 
for bodily pain in the degenerative-spondylolisthe-
sis group vs. 10.2 in the intervertebral-disk-her-
niation study) because of dramatic improvements 
in the nonsurgical group with intervertebral disk 
herniation not seen in the degenerative-spondylo-
listhesis group.
In these nonrandomized comparisons with 
careful control of potentially confounding base-
line factors, patients with persistent neurogenic 
claudication from degenerative spondylolisthesis 
treated surgically showed substantially greater 
improvement in pain and function, as well as 
satisfaction, for 2 years. Characteristics of the 
patients and treatment outcomes were similar in 
the randomized and observational cohorts.
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Figure 2 (facing page). Intention-to-Treat and As-Treat-
ed Results over Time for the Primary Outcome Mea-
sures of SF-36 Bodily Pain (Panels A and B), SF-36 
Physical Function (Panels C and D), and the Oswestry 
Disability Index (Panels E and F). 
SF-36 bodily pain and physical function scores range 
from 0 to 100, with higher scores indicating less severe 
symptoms. The Oswestry Disability Index ranges from 
0 to 100, with lower scores indicating less severe 
symptoms. The horizontal dashed line in each of the 
four SF-36 graphs represents the age- and sex-adjusted 
norms. I bars represent the 95% confidence intervals. 
The floating symbols at 0 months represent the ob-
served mean scores for each treatment group, whereas 
the plotline at 0 months originates from the overall 
mean as used in the adjusted analyses.
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